Covir having highlighted the need to save humanity from the spread of disease that are quick to spread from human to human e.g the dreaded coronavirus (covid-19), has partnered with Octopus Robots in order to finance the production of Biosafety Robots capable of decontaminating the environment.
Follow The Ongoing COVIR IEO On CMC Accredited BITFOREX Exchange
COVIR’s goals as specified in its roadmap and crucial documents is to procure the needed funds required to manufacture Patented Biosafety Robots made by its partner (Octopus Robots). The continuous production and distribution of these robots will help in the decontamination of the environment from different types of transmittable (airborne) and other types of disease.
Different types of Biosafety Robots are being manufactured by Covirs Partner (Octopus Robots) with the aim it will be capable of helping to create a safe environment to humanity when deployed to decontaminate a variety of settings and scenarios that might occur during outbreak of disease.
COVIR aims to leverage on the numerous advantages of blockchain technology towards reaching to the right audience from all parts of the world in a bid to help generate the funds required for the production of the Biosafety Robots and its distribution to all parts of the world thereby helping to create a safe world for everyone.
COVIR through the use of Blockchain technology (Tezos blockchain) and Decontaminating capable Biosafety Robots has laid down the target to works towards securing the needed funds required to manufacture robotic disinfectant systems with international licence and approval in a bid to prevent and treat microbiological contamination in the event of a pandemic or a bioterrorist attack as in the case of covid-19 outbreak.
As recent studies conducted shows an estimated $160 million in potential sales of licenses, Octopus Robots has secured an agreement with COVIR to pre-sell 50% of its licensing rights at a value of $80M
Covir will implement development techniques by tokenizing (Cut in Token) the said $80M which is equivalent to 400,000,000 worth in CVR at a specified rate of $0.20/Unit. As a result, the buyers (investors) of CVR acquire a piece of license rights and finance the production of Biosafety systems in Octopus Robots which will subsequently be sold and invoiced in sales (10% Royalties). Limited Company with capital of 260,000 CHF RC n° ref 09939/2000 n°féd CH-660-1922000-2.
Important Dates to remember for the Ongoing IEO on BITFOREX
Round 1 : 2020/07/31 17:00 (GMT+8) – 2020/08/07 17:00 (GMT+8)
Round 2 : 2020/08/10 17:00 (GMT+8) – 2020/08/14 17:00 (GMT+8)
Subscription Price: $0,20
Subscription Amount (on BitForex):
Round 1: 3,750,000 CVR
Round 2: 3,750,000 CVR
Bonus (based on the subscription amount):
15% CVR bonus for top 50 buyers (for both rounds)
10% CVR bonus for all rest subscribers (for both rounds)
Bonus will be distributed in 7 business days after the end of Subscription by BitForex
CVR/BTC, CVR/USDT trading will open on 2020/08/27 17:00 (GMT+8)
CVR deposit and withdrawal will open on 2020/09/03 17:00 (GMT+8)
Official Exchange Announcement:
More details about COVIR
PURCHASE WITH CREDIT CARD: https://covir.fr/en/covir-cvr-2/
Follow COVIR on all the Social Media Channels